Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 4Leukemia, Promyelocytic, Acute 1

Interventions

Tretinoin 27Arsenic Trioxide 27Cytarabine 20Cyclophosphamide 14Methotrexate 13Idarubicin 13Busulfan 11Filgrastim 10Etoposide 8fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Mercaptopurine 7Gemtuzumab 7Daunorubicin 7Radiotherapy 6Tacrolimus 5Mitoxantrone 5Clofarabine 5Vorinostat 4Topotecan 4Sorafenib 4Antilymphocyte Serum 4Mycophenolic Acid 3Granulocyte Colony-Stimulating Factor 3Bortezomib 3Azacitidine 3venetoclax 2tamibarotene 2sargramostim 2romidepsin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Promyelocytic, Acute × vadastuximab talirine × Clear all
NCT01902329 2018-01-05

A Safety Study of SGN-CD33A in AML Patients

Seagen Inc.

Phase 1 Completed
195 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡